Brodszky Valentin
Budapesti Corvinus Egyetem Egészség-gazdaságtani és Egészségügyi Technológiaelemzési Kutatóközpont Budapest Fővám tér 8. 1093.
Orv Hetil. 2011 Jun 5;152(23):919-28. doi: 10.1556/OH.2011.29138.
The therapy of rheumatoid arthritis has been changed by biological treatments. Their efficacy was evaluated in several randomized controlled trials. These trials were different in patient characteristics and the administration regimen. Placebo was the control and direct comparison of biological treatments is missing.
In the present study the efficacy of biological treatments in patients with rheumatoid arthritis was compared based on the randomized controlled trials available in the literature. A meta-analysis was conducted and meta-regression was used to explore the relationship between disease characteristic variables and observed efficacy.
The related scientific literature is broad. Thirty two trials involving 18,500 patients were included into the current meta-analysis. The relative odds ratios of biological treatments compared to placebo varied between 3.6 and 20.0, and between 6.4 and 35.5 in case of monotherapy and combination with non-biological therapy, respectively. Disease duration and added non-biological therapy were in positive relationship with relative efficacy. More severe disease resulted smaller relative effect.
The results show that the efficacy of biological treatments is similar. The relative efficacy worsens with more severe disease and improves with disease duration.
类风湿关节炎的治疗已因生物治疗而发生改变。其疗效在多项随机对照试验中得到评估。这些试验在患者特征和给药方案方面存在差异。以安慰剂作为对照,生物治疗之间的直接比较缺失。
在本研究中,基于文献中现有的随机对照试验,比较生物治疗对类风湿关节炎患者的疗效。进行了荟萃分析,并使用荟萃回归来探讨疾病特征变量与观察到的疗效之间的关系。
相关科学文献广泛。当前的荟萃分析纳入了32项涉及18500名患者的试验。生物治疗与安慰剂相比的相对优势比在单药治疗时为3.6至20.0,在与非生物治疗联合使用时为6.4至35.5。疾病持续时间和添加的非生物治疗与相对疗效呈正相关。病情越严重,相对疗效越小。
结果表明生物治疗的疗效相似。相对疗效随病情加重而变差,随疾病持续时间延长而改善。